Thales Unveils PureFlyt, the Brain of Tomorrow’s Aircraft
25.11.2019 21:33:00 EET | Business Wire | Press release
Innovdays -Thales is unveiling PureFlyt, the Flight Management System (FMS) of the future, specifically designed to efficiently manage aircraft in a connected aerospace ecosystem and in increasingly crowded skies. Indeed, with the global commercial aircraft fleet forecast to double by 2030, and the use of drones set to rapidly grow, we will be entering an era in which millions of aircraft movements are recorded each day.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191125005715/en/
© Thales
Combining extensive knowledge of Avionics, Connectivity, Air Traffic management and 40-year Flight Management System expertise, Thales has developed PureFlyt, an entirely connected FMS, designed to offer airframers and airlines the best combination of safety, security, and fuel and operations efficiency. PureFlyt will allow crews to make better decisions using more sources of information, will bring improved performance and reactivity to the aircraft during complex phases of flight and will calculate alternative trajectories in real time to propose or react quickly to changes of plan. Providing pilots with the right information at the right time heightens trust in the computed trajectory, enhancing efficiency and reducing pilot workload throughout all flight phases.
One of the core innovations making PureFlyt a game changer in the FMS world is its ability to draw on both onboard and open-world data, such as weather information. By combining the integrity of the FMS and the agility and power of Electronic Flight Bag flight functionalities, aircraft trajectory can be permanently controlled, adapted and enhanced, resulting in optimised flight, decreased fuel consumption and improved passenger comfort.
While being a technological breakthrough, PureFlyt enjoys an unparalleled maturity level. Using massive testing and artificial intelligence technologies to simulate 2 billion test cases enabled accumulating an invaluable experience, equivalent of 100 million actual flight hours.
Cyber-secure by design, PureFlyt has also been designed to be future-proof, accommodating the implementation of concepts such as the Initial 4D (I4D) trajectory management methods currently being researched by SESAR (Single European Sky ATM Research) in the EU and NextGen in the US. By increasing the accuracy of flight in four dimensions, the fourth dimension being time, PureFlyt will enable more effectiveness in maintaining optimal distance between aircraft, particularly in the demanding phases of departure and approach.
PureFlyt will be available for entry into service in 2024, for both linefit and retrofit.
“In the air, the digital revolution has only just begun. A paradigm shift in onboard cockpit electronics is taking place in the connected airspace and PureFlyt is at the forefront of this digital new age, leading the next generation of Flight Management System that truly makes the aircraft a node of connectivity. By computing and sharing vast amounts of data, PureFlyt will make flights safer, greener, easier for the pilots to manage, more profitable for airlines and, all this, ultimately for the full benefits of passengers” declared Jean-Paul Ebanga, Thales Vice-President Flight Avionics.
For more information please visit:
https://www.thalesgroup.com/en/group/magazine/quantum-leap-flight-management
|
About Thales The people we all rely on to make the world go round – they rely on Thales. Our customers come to us with big ambitions: to make life better, to keep us safer. Combining a unique diversity of expertise, talents and cultures, our architects design and deliver extraordinary high technology solutions. Solutions that make tomorrow possible, today. From the bottom of the oceans to the depth of space and cyberspace, we help our customers think smarter and act faster - mastering ever greater complexity and every decisive moment along the way. Thales generated revenues of €19 billion in 2018 with 80,000 employees in 68 countries. |
PLEASE VISIT
Thales Group
Thales Press
Download HD photos
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191125005715/en/
Contact information
PRESS
Thales, Media Relations
Civil Aerospace
Giaime Porcu
+33 1 57 77 92 18
giaime.porcu@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
